logo

For the Inventor, By the Inventor

Newtown, PA, United States of America

T G Murali Dhar

This inventor holds 64 USPTO granted patents and 2 published patent applications and 8 EPO patents, primarily in ROR Gamma Modulators (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Cerep Sa, Exelixis, Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: T G Murali Dhar. Retrieved from https://idiyas.com/inventor/t-g-murali-dhar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 64 

% Patents Active = 98.4

 

Average Co-Inventor Count = 4.7

ph-index = 9

Forward Citations = 244(Granted Patents)

Forward Citations (Not Self Cited) = 221(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Princeton, NJ (US) (2012 - 2018)
  • Newton, PA (US) (2006 - 2020)
  • Newtown, PA (US) (2002 - 2023)

Company Filing History:

goldMedal62 out of 3,742 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal5 out of 5 
 
Cerep Sa
 patents
bronzeMedal1 out of 177 
 
Exelixis, Inc.
 patents
4. 2 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Heterocyclic Compounds
Bicyclic Compounds
ROR Gamma Modulators
Kinase Inhibitors
Sulfone Compounds
Chemokine Receptor Activity
Glucocorticoid Receptor
Tricyclic Compounds
Substituted Compounds
Pyrrolotriazine
Sipi Agonists
Nonsteroidal Compounds
64 patents (USPTO):Explore Patents
1. 12473304 - Heterocyclic PAD4 inhibitors (2025-11-18),
2. 11701373 - Substituted bicyclic compounds (2023-07-18),
3. 11078186 - ROR γ modulators (2021-08-03),
4. 11059784 - Oxime ether compounds (2021-07-13),
5. 11058696 - Substituted bicyclic compounds (2021-07-13),
6. 10968177 - Tricyclic sulfones as RORmodulators (2021-04-06),
7. 10934286 - Heterocyclic sulfones as ROR gamma modulators (2021-03-02),
8. 10865191 - Heterocyclic compounds useful as modulators of TNF alpha (2020-12-15),
9. 10711020 - Tricyclic sulfones as RORγ modulators (2020-07-14),
10. 10709719 - Substituted bicyclic compounds (2020-07-14),
11. 10633354 - Substituted tricyclic heterocyclic compounds (2020-04-28),
12. 10633339 - Tricyclic sulfone compound as a ROR gamma modulator (2020-04-28),
13. 10435369 - Tricyclic sulfones as ROR gamma modulators (2019-10-08),
14. 10273259 - Tricyclic sulfones as RORγ modulators (2019-04-30),
15. 10166249 - Substituted bicyclic compounds (2019-01-01),

Title: T G Murali Dhar: Innovator in Pharmaceutical Patents

Introduction

T G Murali Dhar, based in Newtown, PA, has made significant contributions to the field of pharmaceuticals through his extensive work and numerous patents. With a remarkable portfolio of 63 patents, he has greatly influenced the development of therapeutic compounds that address a range of medical conditions.

Latest Patents

Among his latest innovations are patents related to substituted bicyclic compounds. These compounds, detailed in his recent disclosures, exhibit potential as selective agonists for G protein-coupled receptor S1P. They hold promise for treating, preventing, or slowing the progression of diseases, particularly in autoimmune and vascular therapeutic areas. In addition, he has developed RORγ modulators that are described through a comprehensive formula, which can be used to modulate RORγ activity in cells. These modulators are crucial for treating autoimmune and inflammatory disorders, alongside various pharmaceutical compositions containing these innovative compounds.

Career Highlights

Throughout his career, T G Murali Dhar has held key positions at prominent companies such as Bristol-Myers Squibb Company and Cerep S.A. His contributions in these organizations have propelled advancements in pharmaceutical research and development, showcasing his expertise and dedication to the field.

Collaborations

T G Murali Dhar has collaborated with notable colleagues, including Hai-Yun Xiao and Edwin J Iwanowicz. These partnerships have enhanced his research efforts, leading to groundbreaking discoveries and the successful development of innovative therapeutic solutions.

Conclusion

T G Murali Dhar exemplifies the spirit of innovation in the pharmaceutical industry, with a substantial array of patents that showcase his expertise in creating compounds aimed at treating complex medical conditions. His work continues to make a significant impact, influencing future research and development in therapeutics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…